Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CN201 (Beijing Chengnuo Medical Technology)
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CN201 (also known as ALF201) is an allogeneic cell therapy derived from induced pluripotent stem cells (iPSCs) being developed by Beijing Chengnuo Medical Technology (Allife Medicine). The therapy is variably described as consisting of iPSC-derived endothelial progenitor cells (EPCs) or neural cells, intended to treat acute ischemic stroke. Its mechanism of action involves the transplantation of these cells to replace or repair damaged neural and vascular tissue, promoting functional recovery and neurovascular regeneration following an ischemic event. In April 2022, CN201 received implicit approval from China's Center for Drug Evaluation (CDE), making it the world's first approved clinical iPSC-derived cell candidate for the treatment of acute ischemic stroke. It is currently being evaluated in Phase 1/2 clinical trials.
- Other names
- iPSC-derived Neural Cell TherapyiPSC-derived endothelial progenitor cell therapyAllogeneic iPSC-derived EPC therapy
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CN201 (Beijing Chengnuo Medical Technology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CN201 (Beijing Chengnuo Medical Technology).